Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis
Gespeichert in:
| Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2020-11, Vol.159 (5), p.1985-1987.e4 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1987.e4 |
|---|---|
| container_issue | 5 |
| container_start_page | 1985 |
| container_title | Gastroenterology (New York, N.Y. 1943) |
| container_volume | 159 |
| creator | Noureddin, Mazen Jones, Calum Alkhouri, Naim Gomez, Eduardo Vilar Dieterich, Douglas T. Rinella, Mary E. Therapondos, George Girgrah, Nigel Mantry, Parvez S. Sussman, Norman L. Figueroa Diaz, Viviana Fuchs, Michael |
| description | |
| doi_str_mv | 10.1053/j.gastro.2020.07.050 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2431819739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0016508520350149</els_id><sourcerecordid>2431819739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-9331481586d39eea40617d306efdb73f9b9d756cf99223327334238d14a47f623</originalsourceid><addsrcrecordid>eNp9UU1vEzEQtRAVDYV_gJCPXHbx135xQIpSCpUiQGpzthzvbONoYwePU5T_0h9bR9v22NNI772ZNzOPkE-clZxV8uu2vDOYYigFE6xkTckq9obMeCXagjEu3pJZLnVRsbY6J-8Rt4yxTrb8HTmXoqmlUHxGHm5sBPDO39EhRPo7eDPasAmjs_TKpHSkS3cPkV46BINAnad_IWLwSP-7tKG3xz1QkWmzhgR44tMG6Mq7BD29SeYEXiNdBEwFDAPYlOd9o_OM7PYRNuAxAxO_Sm502XKelziiww_kbDAjwsenekFWVz9uF7-K5Z-f14v5srCKtanopOSq5VVb97IDMIrVvOklq2Ho140cunXXN1Vth64TQubbpVRCtj1XRjVDLeQF-TLN3cfw7wCY9M6hhXE0HsIBtVCSt7xrZJelapLaGBAjDHof3c7Eo-ZMn3LRWz3lok-5aNbonEtu-_zkcFjvoH9peg4iC75PAsh33juIGq0Db6F3Mf9M98G97vAI_E-g8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2431819739</pqid></control><display><type>article</type><title>Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>Alma/SFX Local Collection</source><creator>Noureddin, Mazen ; Jones, Calum ; Alkhouri, Naim ; Gomez, Eduardo Vilar ; Dieterich, Douglas T. ; Rinella, Mary E. ; Therapondos, George ; Girgrah, Nigel ; Mantry, Parvez S. ; Sussman, Norman L. ; Figueroa Diaz, Viviana ; Fuchs, Michael</creator><creatorcontrib>Noureddin, Mazen ; Jones, Calum ; Alkhouri, Naim ; Gomez, Eduardo Vilar ; Dieterich, Douglas T. ; Rinella, Mary E. ; Therapondos, George ; Girgrah, Nigel ; Mantry, Parvez S. ; Sussman, Norman L. ; Figueroa Diaz, Viviana ; Fuchs, Michael ; NASHNET</creatorcontrib><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1053/j.gastro.2020.07.050</identifier><identifier>PMID: 32763241</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cirrhosis ; Cost-Benefit Analysis ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - economics ; Diabetes Mellitus, Type 2 - epidemiology ; Diabetes Mellitus, Type 2 - therapy ; Diagnostic Screening Programs - economics ; Fibrosis ; Health Care Costs ; Healthy Lifestyle ; High-risk population ; Humans ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - economics ; Liver Cirrhosis - epidemiology ; Markov Chains ; Models, Economic ; NASH ; Non-alcoholic Fatty Liver Disease - diagnosis ; Non-alcoholic Fatty Liver Disease - economics ; Non-alcoholic Fatty Liver Disease - epidemiology ; Non-alcoholic Fatty Liver Disease - therapy ; Predictive Value of Tests ; Quality of Life ; Quality-Adjusted Life Years ; Reproducibility of Results ; Risk Factors ; Risk Reduction Behavior ; Screening ; Treatment Outcome ; United States - epidemiology</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 2020-11, Vol.159 (5), p.1985-1987.e4</ispartof><rights>2020 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-9331481586d39eea40617d306efdb73f9b9d756cf99223327334238d14a47f623</citedby><cites>FETCH-LOGICAL-c408t-9331481586d39eea40617d306efdb73f9b9d756cf99223327334238d14a47f623</cites><orcidid>0000-0003-2127-2040</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.gastro.2020.07.050$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32763241$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noureddin, Mazen</creatorcontrib><creatorcontrib>Jones, Calum</creatorcontrib><creatorcontrib>Alkhouri, Naim</creatorcontrib><creatorcontrib>Gomez, Eduardo Vilar</creatorcontrib><creatorcontrib>Dieterich, Douglas T.</creatorcontrib><creatorcontrib>Rinella, Mary E.</creatorcontrib><creatorcontrib>Therapondos, George</creatorcontrib><creatorcontrib>Girgrah, Nigel</creatorcontrib><creatorcontrib>Mantry, Parvez S.</creatorcontrib><creatorcontrib>Sussman, Norman L.</creatorcontrib><creatorcontrib>Figueroa Diaz, Viviana</creatorcontrib><creatorcontrib>Fuchs, Michael</creatorcontrib><creatorcontrib>NASHNET</creatorcontrib><title>Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><subject>Cirrhosis</subject><subject>Cost-Benefit Analysis</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - economics</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Diabetes Mellitus, Type 2 - therapy</subject><subject>Diagnostic Screening Programs - economics</subject><subject>Fibrosis</subject><subject>Health Care Costs</subject><subject>Healthy Lifestyle</subject><subject>High-risk population</subject><subject>Humans</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - economics</subject><subject>Liver Cirrhosis - epidemiology</subject><subject>Markov Chains</subject><subject>Models, Economic</subject><subject>NASH</subject><subject>Non-alcoholic Fatty Liver Disease - diagnosis</subject><subject>Non-alcoholic Fatty Liver Disease - economics</subject><subject>Non-alcoholic Fatty Liver Disease - epidemiology</subject><subject>Non-alcoholic Fatty Liver Disease - therapy</subject><subject>Predictive Value of Tests</subject><subject>Quality of Life</subject><subject>Quality-Adjusted Life Years</subject><subject>Reproducibility of Results</subject><subject>Risk Factors</subject><subject>Risk Reduction Behavior</subject><subject>Screening</subject><subject>Treatment Outcome</subject><subject>United States - epidemiology</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1vEzEQtRAVDYV_gJCPXHbx135xQIpSCpUiQGpzthzvbONoYwePU5T_0h9bR9v22NNI772ZNzOPkE-clZxV8uu2vDOYYigFE6xkTckq9obMeCXagjEu3pJZLnVRsbY6J-8Rt4yxTrb8HTmXoqmlUHxGHm5sBPDO39EhRPo7eDPasAmjs_TKpHSkS3cPkV46BINAnad_IWLwSP-7tKG3xz1QkWmzhgR44tMG6Mq7BD29SeYEXiNdBEwFDAPYlOd9o_OM7PYRNuAxAxO_Sm502XKelziiww_kbDAjwsenekFWVz9uF7-K5Z-f14v5srCKtanopOSq5VVb97IDMIrVvOklq2Ho140cunXXN1Vth64TQubbpVRCtj1XRjVDLeQF-TLN3cfw7wCY9M6hhXE0HsIBtVCSt7xrZJelapLaGBAjDHof3c7Eo-ZMn3LRWz3lok-5aNbonEtu-_zkcFjvoH9peg4iC75PAsh33juIGq0Db6F3Mf9M98G97vAI_E-g8Q</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Noureddin, Mazen</creator><creator>Jones, Calum</creator><creator>Alkhouri, Naim</creator><creator>Gomez, Eduardo Vilar</creator><creator>Dieterich, Douglas T.</creator><creator>Rinella, Mary E.</creator><creator>Therapondos, George</creator><creator>Girgrah, Nigel</creator><creator>Mantry, Parvez S.</creator><creator>Sussman, Norman L.</creator><creator>Figueroa Diaz, Viviana</creator><creator>Fuchs, Michael</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2127-2040</orcidid></search><sort><creationdate>202011</creationdate><title>Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis</title><author>Noureddin, Mazen ; Jones, Calum ; Alkhouri, Naim ; Gomez, Eduardo Vilar ; Dieterich, Douglas T. ; Rinella, Mary E. ; Therapondos, George ; Girgrah, Nigel ; Mantry, Parvez S. ; Sussman, Norman L. ; Figueroa Diaz, Viviana ; Fuchs, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-9331481586d39eea40617d306efdb73f9b9d756cf99223327334238d14a47f623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cirrhosis</topic><topic>Cost-Benefit Analysis</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - economics</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Diabetes Mellitus, Type 2 - therapy</topic><topic>Diagnostic Screening Programs - economics</topic><topic>Fibrosis</topic><topic>Health Care Costs</topic><topic>Healthy Lifestyle</topic><topic>High-risk population</topic><topic>Humans</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - economics</topic><topic>Liver Cirrhosis - epidemiology</topic><topic>Markov Chains</topic><topic>Models, Economic</topic><topic>NASH</topic><topic>Non-alcoholic Fatty Liver Disease - diagnosis</topic><topic>Non-alcoholic Fatty Liver Disease - economics</topic><topic>Non-alcoholic Fatty Liver Disease - epidemiology</topic><topic>Non-alcoholic Fatty Liver Disease - therapy</topic><topic>Predictive Value of Tests</topic><topic>Quality of Life</topic><topic>Quality-Adjusted Life Years</topic><topic>Reproducibility of Results</topic><topic>Risk Factors</topic><topic>Risk Reduction Behavior</topic><topic>Screening</topic><topic>Treatment Outcome</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noureddin, Mazen</creatorcontrib><creatorcontrib>Jones, Calum</creatorcontrib><creatorcontrib>Alkhouri, Naim</creatorcontrib><creatorcontrib>Gomez, Eduardo Vilar</creatorcontrib><creatorcontrib>Dieterich, Douglas T.</creatorcontrib><creatorcontrib>Rinella, Mary E.</creatorcontrib><creatorcontrib>Therapondos, George</creatorcontrib><creatorcontrib>Girgrah, Nigel</creatorcontrib><creatorcontrib>Mantry, Parvez S.</creatorcontrib><creatorcontrib>Sussman, Norman L.</creatorcontrib><creatorcontrib>Figueroa Diaz, Viviana</creatorcontrib><creatorcontrib>Fuchs, Michael</creatorcontrib><creatorcontrib>NASHNET</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noureddin, Mazen</au><au>Jones, Calum</au><au>Alkhouri, Naim</au><au>Gomez, Eduardo Vilar</au><au>Dieterich, Douglas T.</au><au>Rinella, Mary E.</au><au>Therapondos, George</au><au>Girgrah, Nigel</au><au>Mantry, Parvez S.</au><au>Sussman, Norman L.</au><au>Figueroa Diaz, Viviana</au><au>Fuchs, Michael</au><aucorp>NASHNET</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>2020-11</date><risdate>2020</risdate><volume>159</volume><issue>5</issue><spage>1985</spage><epage>1987.e4</epage><pages>1985-1987.e4</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32763241</pmid><doi>10.1053/j.gastro.2020.07.050</doi><orcidid>https://orcid.org/0000-0003-2127-2040</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0016-5085 |
| ispartof | Gastroenterology (New York, N.Y. 1943), 2020-11, Vol.159 (5), p.1985-1987.e4 |
| issn | 0016-5085 1528-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2431819739 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); Alma/SFX Local Collection |
| subjects | Cirrhosis Cost-Benefit Analysis Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - economics Diabetes Mellitus, Type 2 - epidemiology Diabetes Mellitus, Type 2 - therapy Diagnostic Screening Programs - economics Fibrosis Health Care Costs Healthy Lifestyle High-risk population Humans Liver Cirrhosis - diagnosis Liver Cirrhosis - economics Liver Cirrhosis - epidemiology Markov Chains Models, Economic NASH Non-alcoholic Fatty Liver Disease - diagnosis Non-alcoholic Fatty Liver Disease - economics Non-alcoholic Fatty Liver Disease - epidemiology Non-alcoholic Fatty Liver Disease - therapy Predictive Value of Tests Quality of Life Quality-Adjusted Life Years Reproducibility of Results Risk Factors Risk Reduction Behavior Screening Treatment Outcome United States - epidemiology |
| title | Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T16%3A51%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Screening%20for%20Nonalcoholic%20Fatty%20Liver%20Disease%20in%20Persons%20with%20Type%202%20Diabetes%20in%20the%20United%20States%20Is%20Cost-effective:%20A%20Comprehensive%20Cost-Utility%20Analysis&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Noureddin,%20Mazen&rft.aucorp=NASHNET&rft.date=2020-11&rft.volume=159&rft.issue=5&rft.spage=1985&rft.epage=1987.e4&rft.pages=1985-1987.e4&rft.issn=0016-5085&rft.eissn=1528-0012&rft_id=info:doi/10.1053/j.gastro.2020.07.050&rft_dat=%3Cproquest_cross%3E2431819739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2431819739&rft_id=info:pmid/32763241&rft_els_id=S0016508520350149&rfr_iscdi=true |